Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zelos Therapeutics and Aegis Therapeutics have signed a collaboration agreement for the development of an intranasal spray formulation of the proprietary parathyroid hormone analog ZT-031.
Subscribe to our email newsletter
Under the collaboration, which is exclusive across the parathyroid hormone (PTH) field, Zelos will utilize Aegis’s patented Intravail permeation enhancer technology to develop an intranasal version of ZT-031 for the treatment of osteoporosis and other bone diseases. A subcutaneous formulation of ZT-031 has already successfully completed a 12 month Phase II clinical trial in the treatment of osteoporosis.
Edward Maggio, CEO of Aegis, said: “Aegis looks forward to collaborating with Zelos on the development of intranasal ZT-031. The unique and differentiated product profile and strong clinical results for ZT-031 are impressive, and we believe this PTH analog is an ideal match for our Intravail technology.”